Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 5/2004

01-09-2004 | Therapy Review

Islet Transplantation in Patients with Diabetes Mellitus

Choice of Immunosuppression

Authors: Sulaiman A. Nanji, A.M. James Shapiro

Published in: BioDrugs | Issue 5/2004

Login to get access

Abstract

Islet transplantation offers patients with type 1 diabetes mellitus freedom from long-term insulin therapy and a degree of metabolic control that is far superior to injected insulin. The hope is that near-perfect glucose control sustained over time will prevent progression of secondary diabetic complications. The selection of optimal immunosuppressive agents for islet transplantation has been a formidable challenge, given the need to overcome both autoimmune and alloimmune barriers, as well as the potential toxicity of immunosuppressive agents on transplanted islets. Early strategies relied on protocols that had proven success in solid organ transplantation and consisted of azathioprine, cyclosporine and corticosteroids. Under these protocols, fewer than 10% of patients were able to achieve insulin independence. The development of the “Edmonton Protocol’ dramatically transformed clinical outcomes in islet transplantation in recent years through the introduction of a more potent, less diabetogenic, and corticosteroid-free immunosuppressive regimen consisting of sirolimus, low-dose tacrolimus, and induction anti-interleukin-2 receptor antibody. While insulin independence rates under this protocol have been highly successful, patients must be maintained on lifelong immunosuppression. While the risk of malignancy, post-transplant lymphoma and sepsis have been low and diminishing in transplanted patients to date, fears of these complications and a host of drug-related adverse effects have precluded broader application. Patients undergoing islet transplantation today must exchange insulin for chronic immunosuppressive therapy, and therefore the procedure can only be justified in patients with very unstable forms of diabetes, or in those with another solid organ allograft who already endure the risks of immunosuppression. Advances in more specific and less toxic immunosuppressive agents together with progress in better understanding the biology of diabetes will lead to more suitable strategies to control both alloimmune and recurrent autoimmune reactions. These protocols, ultimately aimed at establishing tolerance, are an essential pre-requisite to move towards providing islet transplantation earlier in the course of the disease, including transplantation in children. This review addresses the evolution of immunosuppressive strategies in islet transplantation, and highlights some novel agents in pre-clinical development or in early clinical trials that may offer considerable promise in facilitating the induction of tolerance.
Literature
1.
Williams P. Notes on diabetes treated with extract and by grafts of sheep’s pancreas. BMJ 1894; 2: 1303–4
2.
Banting F. Extract from Banting’s notebook 2am October 31st. Canada: Academy of Medicine notebook, Archives of Toronto University, 1920
3.
Bliss M. The discovery of insulin. Toronto: McClelland and Stewart Limited, 1982
4.
Lacy P, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16: 35–9PubMed
5.
Najarian JS, Sutherland DE, Matas AJ, et al. Human islet transplantation: a preliminary report. Transplant Proc 1977; 9(1): 233–6PubMed
6.
Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37(4): 413–20PubMedCrossRef
7.
Robertson GS, Chadwick DR, Contractor H, et al. The optimization of large-scale density gradient isolation of human islets. Acta Diabetol 1993; 30(2): 93–8PubMedCrossRef
8.
Linetsky E, Bottino R, Lehmann R, et al. Improved human islet isolation using a new enzyme blend, liberase. Diabetes 1997; 46(7): 1120–3PubMedCrossRef
9.
Brendel M, Hering B, Schulz A, et al. International islet transplant registry report. University of Giessen, Germany; 1999. Newsletter No. 8
10.
Boker A, Rothenberg L, Hernandez C, et al. Human islet transplantation: update. World J Surg 2001; 25(4): 481–6PubMedCrossRef
11.
Hering B, Ricordi C. Islet transplantation for patients with type 1 diabetes: results, research priorities, and reasons for optimism. Graft 1999; 2(1): 12–27
12.
Kaufman DB, Morel P, Condie R, et al. Beneficial and detrimental effects of RBC-adsorbed antilymphocyte globulin and prednisone on purified canine islet autograft and allograft function. Transplantation 1991; 51(1): 37–42PubMedCrossRef
13.
Rilo HL, Carroll PB, Zeng YJ, et al. Acceleration of chronic failure of intrahepatic canine islet autografts by a short course of prednisone. Transplantation 1994; 57(2): 181–7PubMedCrossRef
14.
Zeng Y, Ricordi C, Lendoire J, et al. The effect of prednisone on pancreatic islet autografts in dogs. Surgery 1993; 113(1): 98–102PubMed
15.
Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343(4): 230–8PubMedCrossRef
16.
Shapiro AM, Ricordi C, Hering B. Edmonton’s islet success has indeed been replicated elsewhere. Lancet 2003; 362(9391): 1242PubMedCrossRef
17.
Borel JF, Feurer C, Magnee C, et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977; 32(6): 1017–25PubMed
18.
Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; II(8151): 1033–6CrossRef
19.
Halloran PF, Madrenas J. The mechanism of action of cyclosporine: a perspective for the 90’s. Clin Biochem 1991; 24(1): 3–7PubMedCrossRef
20.
Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357(6380): 695–7PubMedCrossRef
21.
Northrop JP, Ho SN, Chen L, et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 1994; 369(6480): 497–502PubMedCrossRef
22.
Gunnarsson R, Klintmalm G, Lundgren G, et al. Deterioration in glucose metabolism in pancreatic transplant recipients after conversion from azathioprine to cyclosporine. Transplant Proc 1984; 16(3): 709–12PubMed
23.
Andersson A, Borg H, Hallberg A, et al. Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Diabetologia 1984; 27Suppl. 1: 66–9PubMedCrossRef
24.
Robertson RP. Cyclosporin-induced inhibition of insulin secretion in isolated rat islets and HIT cells. Diabetes 1986; 35(9): 1016–9PubMedCrossRef
25.
Nielsen JH, Mandrup-Poulsen T, Nerup J. Direct effects of cyclosporin A on human pancreatic β-cells. Diabetes 1986; 35(9): 1049–52PubMedCrossRef
26.
Hahn HJ, Dunger A, Laube F, et al. Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia 1986; 29(8): 489–94PubMedCrossRef
27.
Helmchen U, Schmidt WE, Siegel EG, et al. Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats. Diabetologia 1984; 27(3): 416–8PubMedCrossRef
28.
Eun HM, Pak CY, Kim CJ, et al. Role of cyclosporin A in macromolecular synthesis of beta-cells. Diabetes 1987; 36(8): 952–8PubMedCrossRef
29.
Garvin PJ, Niehoff M, Staggenborg J. Cyclosporine’s effect on canine pancreatic endocrine function. Transplantation 1988; 45(6): 1027–31PubMedCrossRef
30.
Kneteman NM, Marchetti P, Tordjman K, et al. Effects of cyclosporine on insulin secretion and insulin sensitivity in dogs with intrasplenic islet autotransplants. Surgery 1992; 111(4): 430–7PubMed
31.
Alejandro R, Feldman EC, Bloom AD, et al. Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes 1989; 38(6): 698–703PubMedCrossRef
32.
Jindal RM. Posttransplant diabetes mellitus: a review. Transplantation 1994; 58(12): 1289–98PubMed
33.
Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70(11 Suppl.): SS58–63PubMed
34.
Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44(3): 376–81PubMedCrossRef
35.
Teuscher AU, Seaquist ER, Robertson RP. Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 1994; 43(4): 593–8PubMedCrossRef
36.
Ziel FH, Venkatesan N, Davidson MB. Glucose transport is rate limiting for skeletal muscle glucose metabolism in normal and STZ-induced diabetic rats. Diabetes 1988; 37(7): 885–90PubMedCrossRef
37.
Venkatesan N, Davidson MB, Hutchinson A. Possible role for the glucose-fatty acid cycle in dexamethasone-induced insulin antagonism in rats. Metabolism 1987; 36(9): 883–91PubMedCrossRef
38.
Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 1982; 54(1): 131–8PubMedCrossRef
39.
Munck A. Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new evidence, molecular mechanisms, and physiological significance. Perspect Biol Med 1971; 14(2): 265–9PubMed
40.
Ochiai T, Nagata M, Nakajima K, et al. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation 1987; 44(6): 729–33PubMedCrossRef
41.
Ost L. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. Transplantation 1987; 44(4): 533–5PubMedCrossRef
42.
Ricordi C, Tzakis AG, Carroll PB, et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 1992; 53(2): 407–14PubMedCrossRef
43.
Maffi P, Bertuzzi F, Guiducci D, et al. Per and peri-operative management influences the clinical outcome of islet transplantation. Am J Transplant 2001; 1(1 Suppl. 1): 181
44.
Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31(5): 335–40PubMedCrossRef
45.
Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17(6): 660–5PubMedCrossRef
46.
Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987; 19 (1 Pt 2): 1284–6PubMed
47.
Yoshimura N, Matsui S, Hamashima T, et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro: I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 1989; 47(2): 351–6PubMedCrossRef
48.
Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; II(8670): 1000–4CrossRef
49.
Fung J, Todo S, Abu-Elmagd K, et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. Transplant Proc 1993; 25(1 Pt 2): 1130PubMed
50.
European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344(8920): 423–8CrossRef
51.
Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66(4): 493–9PubMedCrossRef
52.
Rilo HL, Carroll PB, Tzakis A, et al. Insulin independence for 58 months following pancreatic islet cell transplantation in a patient undergoing upper abdominal exenteration. Transplant Proc 1995; 27(6): 3164–5PubMed
53.
Carroll PB, Rilo HL, Alejandro R, et al. Long-term (> 3-year) insulin independence in a patient with pancreatic islet cell transplantation following upper abdominal exenteration and liver replacement for fibrolamellar hepatocellular carcinoma. Transplantation 1995; 59(6): 875–9PubMed
54.
Scharp DW, Lacy PE, Santiago JV, et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 1991; 51(1): 76–85PubMedCrossRef
55.
Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. Transplantation 1993; 56(6): 1293–8PubMedCrossRef
56.
Shibata S, Matsumoto S, Sageshima J, et al. Temporary treatment with sirolimus and low-trough cyclosporine prevents acute islet allograft rejection, and combination with starch-conjugated deferoxamine promotes islet engraftment in the preclinical pig model. Transplant Proc 2001; 33(1-2): 509PubMedCrossRef
57.
Kahan BD. Concentration-controlled immunosuppressive regimens using cyclosporine with sirolimus or brequinar in human renal transplantation. Transplant Proc 1995; 27(1): 33–6PubMed
58.
Vu MD, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64(12): 1853–6PubMedCrossRef
59.
Chen H, Qi S, Xu D, et al. Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse. Transplant Proc 1998; 30(6): 2579–81PubMedCrossRef
60.
McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355(9201): 376–7PubMedCrossRef
61.
Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773–80PubMedCrossRef
62.
Tkaczuk J, Milford E, Yu C, et al. Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab. Transplant Proc 2001; 33(1-2): 212–3PubMedCrossRef
63.
Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322(17): 1175–82PubMedCrossRef
64.
Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplant Proc 1991; 23(1 Pt 2): 1066–7PubMed
65.
Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation 1999; 67(1): 110–5PubMedCrossRef
66.
Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action: double therapy and the Triple Therapy Study Groups. Transplant Proc 1998; 30(5): 2155–8PubMedCrossRef
67.
Ekberg H, Backman L, Tufveson G, et al. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int 2000; 13(2): 151–9PubMedCrossRef
68.
Stratta RJ, Taylor RJ, Castaldo P, et al. Preliminary experience with FK 506 in pancreas transplant recipients. Transplant Proc 1995; 27(6): 3024PubMed
69.
Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 2001; 233(4): 463–501PubMedCrossRef
70.
Wohlrab J, Fischer M, Taube KM, et al. Treatment of recalcitrant psoriasis with daclizumab. Br J Dermatol 2001; 144(1): 209–10PubMedCrossRef
71.
Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51(7): 2148–57PubMedCrossRef
72.
Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63(1): 1–6PubMedCrossRef
73.
Contreras JL, Wang PX, Eckhoff DE, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 1998; 65(9): 1159–69PubMedCrossRef
74.
Thomas JM, Contreras JL, Jiang XL, et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999; 68(11): 1660–73PubMedCrossRef
75.
Contreras JL, Eckhoff DE, Cartner S, et al. Long-term functional islet mass and metabolic function after xenoislet transplantation in primates. Transplantation 2000; 69(2): 195–201PubMedCrossRef
76.
Thomas FT, Ricordi C, Contreras JL, et al. Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 1999; 67(6): 846–54PubMedCrossRef
77.
Thomas JM, Contreras JL, Smyth CA, et al. Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of type 1 diabetes. Diabetes 2001; 50(6): 1227–36PubMedCrossRef
78.
Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158(6): 2947–54PubMed
79.
Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346(22): 1692–8PubMedCrossRef
80.
Herold KC, Burton JB, Francois F, et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gammal(Ala-Ala). J Clin Invest 2003; 111(3): 409–18PubMed
81.
Hering BJ, Matsumoto I, Sawada T, et al. Impact of two-layer pancreas preservation on islet isolation and transplantation. Transplantation 2002; 74(12): 1813–6PubMedCrossRef
82.
Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003; 30(4): 424–33PubMedCrossRef
83.
Lockwood CM, Thiru S, Isaacs JD, et al. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993; 341(8861): 1620–2PubMedCrossRef
84.
Coles AJ, Wing MG, Compston DA. Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy. Mult Scler 1998; 4(3): 232–8PubMed
85.
Killick SB, Marsh JC, Hale G, et al. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br J Haematol 1997; 97(2): 306–8PubMedCrossRef
86.
Lim SH, Hale G, Marcus RE, et al. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 1993; 84(3): 542–4PubMedCrossRef
87.
Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68(10): 1613–6PubMedCrossRef
88.
Calne R, Moffatt SD, Friend PJ, et al. Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Nippon Geka Gakkai Zasshi 2000; 101(3): 301–6PubMed
89.
Knechtle SJ, Pirsch JD, Fechner JJH, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3(6): 722–30PubMedCrossRef
90.
Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356(6370): 607–9PubMedCrossRef
91.
Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233–58PubMedCrossRef
92.
Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248(4961): 1349–56PubMedCrossRef
93.
Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159(11): 5187–91PubMed
94.
Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 1999; 96(14): 8132–7PubMedCrossRef
95.
Kenyon NS, Fernandez LA, Lehmann R, et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD 154. Diabetes 1999; 48(7): 1473–81PubMedCrossRef
96.
Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999; 162(8): 4983–90PubMed
97.
Knosalla C, Gollackner B, Cooper DK. Anti-CD154 monoclonal antibody and thromboembolism revisted. Transplantation 2002; 74(3): 416–7PubMedCrossRef
98.
Buhler L, Alwayn IP, Appel JZ, et al. Anti-CD 154 monoclonal antibody and thromboembolism. Transplantation 2001; 71(3): 491PubMedCrossRef
99.
Garlichs CD, Geis T, Goppelt-Struebe M, et al. Induction of cyclooxygenase-2 and enhanced release of prostaglandin E(2) and I(2) in human endothelial cells by engagement of CD40. Atherosclerosis 2002; 163(1): 9–16PubMedCrossRef
100.
Szabolcs MJ, Cannon PJ, Thienel U, et al. Analysis of CD154 and CD40 expression in native coronary atherosclerosis and transplant associated coronary artery disease. Virchows Arch 2000; 437(2): 149–59PubMedCrossRef
101.
Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997; 9(5): 641–7PubMedCrossRef
102.
Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74(7): 933–40PubMedCrossRef
103.
Adams AB, Shirasugi N, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51(2): 265–70PubMedCrossRef
104.
Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001; 2(3): 203–9PubMedCrossRef
105.
Nanji S, Hancock WW, Anderson CC, et al. Multiple combination therapies involving blockade of ICOS/B7R-1 costimulation facilitate long-term islet allograft survival. Am J Transplant 2004; 4(4): 526–36PubMedCrossRef
106.
Nakamura Y, Yasunami Y, Satoh M, et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. Transplantation 2003; 75(8): 1115–8PubMedCrossRef
107.
Gao W, Demirci G, Li XC. Negative T cell costimulation and islet tolerance. Diabetes Metab Res Rev 2003; 19(3): 179–85PubMedCrossRef
108.
Gao W, Demirci G, Strom TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003; 76(6): 994–9PubMedCrossRef
109.
Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 2001; 166(1): 322–9PubMed
110.
Basadonna GP, Auersvald L, Khuong CQ, et al. Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci U S A 1998; 95(7): 3821–6PubMedCrossRef
111.
Auersvald LA, Rothstein DM, Oliveira SC, et al. Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. Transplantation 1997; 63(9): 1355–8PubMedCrossRef
112.
Auersvald LA, Rothstein DM, Oliveira SC, et al. Anti-CD45RB treatment prolongs islet allograft survival in mice. Transplant Proc 1997; 29(1-2): 771PubMedCrossRef
113.
Shapiro ME, Liu M. Prolongation of islet allograft survival by anti-CD45 antibody pretreatment. Transplant Proc 1995; 27(1): 613–4PubMed
114.
Molano RD, Berney T, Pileggi A, et al. Prolonged survival of allogeneic islet grafts in NOD mice treated with a combination of anti-CD45RB and anti-CD154 antibodies. Transplant Proc 2001; 33(1-2): 248–9PubMedCrossRef
115.
Molano RD, Pileggi A, Berney T, et al. Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154. Diabetes 2003; 52(4): 957–64PubMedCrossRef
116.
Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5(6): 686–93PubMedCrossRef
117.
Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5(11): 1298–302PubMedCrossRef
118.
Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5(11): 1303–7PubMedCrossRef
119.
Nelson PJ, Krensky AM. Chemokines and allograft rejection: narrowing the list of suspects. Transplantation 2001; 72(7): 1195–7PubMedCrossRef
120.
Hancock WW, Gao W, Faia KL, et al. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12(5): 511–6PubMedCrossRef
121.
Abdi R, Means TK, Luster AD. Chemokines in islet allograft rejection. Diabetes Metab Res Rev 2003; 19(3): 186–90PubMedCrossRef
122.
Lee I, Wang L, Wells AD, et al. Blocking the monocyte chemoattractant protein-1/ CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003; 171(12): 6929–35PubMed
123.
Abdi R, Smith RN, Makhlouf L, et al. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 2002; 51(8): 2489–95PubMedCrossRef
124.
Baker MS, Chen X, Rotramel AR, et al. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 2003; 134(2): 126–33PubMedCrossRef
125.
Brinkmann V, Pinschewer D, Chiba K, et al. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000; 21(2): 49–52PubMedCrossRef
126.
Brinkmann V, Pinschewer DD, Feng L, et al. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 2001; 72(5): 764–9PubMedCrossRef
127.
Brinkmann V, Chen S, Feng L, et al. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 2001; 33(1-2): 530–1PubMedCrossRef
128.
Chiba K, Hoshino Y, Suzuki C, et al. FTY720, a novel immunosuppressant possessing unique mechanisms: I. prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 1996; 28(2): 1056–9PubMed
129.
Xu M, Pirenne J, Antoniou EA, et al. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation. Transpl Int 1998; 11(4): 288–94PubMedCrossRef
130.
Stepkowski SM, Wang M, Qu X, et al. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival. Transplant Proc 1998; 30(5): 2214–6PubMedCrossRef
131.
Hoshino Y, Suzuki C, Ohtsuki M, et al. FTY720, a novel immunosuppressant possessing unique mechanisms: II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 1996; 28(2): 1060–1PubMed
132.
Schuurman HJ, Menninger K, Audet M, et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation 2002; 74(7): 951–60PubMedCrossRef
133.
Fu F, Hu S, Li S, et al. FTY720, a novel immunosuppressive agent with insulinotropic activity, prolongs graft survival in a mouse islet transplantation model. Transplant Proc 2001; 33(1-2): 672–3PubMedCrossRef
134.
Fu F, Hu S, Deleo J, et al. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 2002; 73(9): 1425–30PubMedCrossRef
135.
Wijkstrom M, Kenyon NS, Kirchhof N, et al. Islat allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 2004; 77(6): 827–35PubMedCrossRef
136.
Maki T, Gottschalk R, Monaco AP. Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 2002; 74(12): 1684–6PubMedCrossRef
137.
Bennet W, Groth CG, Larsson R, et al. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000; 105(2): 125–33PubMed
138.
Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360 (9350): 2039–45CrossRef
139.
Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51(6): 1779–84PubMedCrossRef
140.
Goto M, Johansson H, Maeda A, et al. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation 2004; 77(5): 741–7PubMedCrossRef
141.
Farney AC, Xenos E, Sutherland DE, et al. Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc 1993; 25(1 Pt 2): 865–6PubMed
142.
Brandhorst D, Brandhorst H, Zwolinski A, et al. High-dosed nicotinamide decreases early graft failure after pig to nude rat intraportal islet transplantation. Transplantation 2002; 73(1): 74–9PubMedCrossRef
143.
Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000; 43(11): 1337–45PubMedCrossRef
144.
Gysemans C, Van Etten E, Overbergh L, et al. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1alpha, 25-dihydroxyvitamin-D3. Clin Exp Immunol 2002; 128(2): 213–20PubMedCrossRef
145.
Riachy R, Vandewalle B, Belaich S, et al. Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets. J Endocrinol 2001; 169(1): 161–8PubMedCrossRef
146.
Contreras JL, Smyth CA, Bilbao G, et al. Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation 2002; 74(8): 1063–9PubMedCrossRef
147.
Arita S, Nagai T, Ochiai M, et al. Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin. Transplantation 2002; 73(1): 7–12PubMedCrossRef
148.
Auchincloss H. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001; 1(1): 6–12PubMedCrossRef
149.
Adams AB, Shirasugi N, Jones TR, et al. Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance induction. Am J Transplant 2003; 3(7): 895–901PubMedCrossRef
150.
Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74(10): 1405–9PubMedCrossRef
151.
Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991;114(11): 954–5PubMed
152.
Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68(4): 480–4PubMedCrossRef
153.
Sykes M, Spitzer TR. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies. Cancer Treat Res 2002; 110: 79–99PubMedCrossRef
154.
Seung E, Iwakoshi N, Woda BA, et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000; 95(6): 2175–82PubMed
155.
Li H, Inverardi L, Molano RD, et al. Nonlethal conditioning for the induction of allogeneic chimerism and tolerance to islet allografts. Transplantation 2003; 75(7): 966–70PubMedCrossRef
156.
Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361(9368): 1502–10PubMedCrossRef
157.
Oike F, Yokoi A, Nishimura E, et al. Complete withdrawal of immunosuppression in living donor liver transplantation. Transplant Proc 2002; 34(5): 1521PubMedCrossRef
158.
Tanaka K, Kiuchi T. Living-donor liver transplantation in the new decade: perspective from the twentieth to the twenty-first century. J Hepatobiliary Pancreat Surg 2002; 9(2): 218–22PubMedCrossRef
Metadata
Title
Islet Transplantation in Patients with Diabetes Mellitus
Choice of Immunosuppression
Authors
Sulaiman A. Nanji
A.M. James Shapiro
Publication date
01-09-2004
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 5/2004
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.2165/00063030-200418050-00004

Other articles of this Issue 5/2004

BioDrugs 5/2004 Go to the issue

Apis Spotlight

Spotlight on Interferon-β-1b in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

Novel Therapeutic Strategies

Therapeutic Potential of Toleragens in the Management of Antiphospholipid Syndrome

Therapy Review

Current Concepts in the Therapy of the Spondyloarthritides

Drug Mechanisms and Targets

Potassium Channels in T Lymphocytes

Drug Development

Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals